Is BAYZF.PK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk Description

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, June 6, 6:12 AM Regeneron (REGN) and Bayer's (BAYZF.PK) Eylea treatment helped improve the clearness of patients' vision in those with myopic choroidal neovascularization (mCNV) in a Phase III trial. mCNV is a disease where abnormal blood vessels grow into the retina in people who are severely short-sighted. Bayer now expects to submit the first application for regulatory approval of Eylea for mCNV in Asia in H2. (PR) Comment! [Healthcare]
Wednesday, June 5, 8:31 AM Conceptus (CPTS) stockholders tender 96% of the company's shares to Bayer (BAYZF.PK) in the latter's $1.1B acquisition of the maker of female sterilization devices. Bayer now plans to merge Conceptus with one of its subsidiaries. (PR) Comment! [M&A, Healthcare]
Monday, June 3, 5:47 AM Bayer's (BAYZF.PK) and Onyx Pharmaceuticals' Nexavar drug helped prevent a rare type of thyroid cancer from getting worse for 10.8 months in patients a Phase III study, well above the 5.8 months in subjects who took a placebo. However, Nexavar didn't improve overall survival rates. Authorized sales to thyroid cancer sufferers could add $200-300M to sales of Nexavar, which is already approved to treat liver and kidney cancer. (PR) The findings were presented at the annual meeting of the American Society of Clinical Oncology. Comment! [Healthcare]
Wednesday, May 29, 8:20 AM Germany's Bayer (BAYZF.PK) has received antitrust clearance from the FTC for its $1.1B acquisition of U.S. contraceptive devices maker Conceptus. The deal is now contingent on Conceptus' stockholders tendering a majority of the outstanding shares in the firm. Comment! [Healthcare, M&A]
Monday, April 29, 5:32 AM Bayer AG (BAYZF.PK) says it will acquire Conceptus (CPTS) for $1.1B in a deal that will pay CPTS shareholders $31 per share in cash, a near 20% premium to Friday's close. With the deal, Bayer gets CPTS' surgery free, permanent birth control method, expanding its portfolio of contraceptive offerings. Comment! [M&A, Healthcare]
Tuesday, April 16, 4:44 PM Actavis (ACT) rallies +1% into the close after an appeals court rules in the company's favor regarding a patent dispute with Bayer (BAYZF.PK). Actavis yanked its generic version of the contraceptive Yaz from pharmacies last year after Bayer successfully challenged it on patent infringement grounds in a Nevada court. Comment! [Healthcare]
Thursday, February 28, 8:24 AM Bayer (BAYZF.PK): Q4 net profit slips 5.8% to €374M. Adjusted EPS €1 vs €0.97. Underlying EBITDA +18.4% to €1.83B, in line. Revenue +7.3% to €9.86B, slightly above consensus. Expects 2013 underlying EBITDA growth in the mid-single-digits vs forecasts of 8%, and for adjusted EPS to increase by high-single-digits. Forecasts annual sales of over €2.5B for five key drugs by 2015, which is better than previously expected. Shares +1.8% to €75.40 in Frankfurt. (PR) Comment! [Earnings, Healthcare]
Thursday, February 14, 8:23 AM More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of $53.4M as sales more than triple, with its Eylea eyecare product bringing in $276M. Earnings also include $127M in collaboration revenues and a non-cash tax benefit of $336M. Forecasts 2013 Eyelea sales of $1.2-1.3B in the U.S. Partner Bayer has started to launch the product overseas. (PR) 1 Comment [Earnings, Healthcare]
Wednesday, January 23, 4:06 AM More on Novartis (NVS) Q4: Chairman Daniel Vasella will resign and will be replaced by senior Bayer health-care executive Joerg Reinhardt, who was formerly COO at Novartis. Provides mid-term guidance for the first time, forecasting mid-single-digit percentage fall in core earnings this year; sales to be in line with 2012, excluding currency swings, although generic competition will eat into revenue by up to $3.5B. Sales growth to resume in 2014 and 2015. Comment! [Earnings, Healthcare]
Sunday, December 9, 2012, 3:28 AM Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in veins and lungs, and death, by 81% compared with a placebo in major year-long trial. Bleeding was also low. BMY could rack up sales of $4.18B by 2018 if Eliquis is approved - the drug would compete with warfarin, Xarelto from Bayer and J&J (JNJ), and Pradaxa from Boehringer Ingelheim. (PR) 5 Comments [Healthcare, Top Stories]
Tuesday, November 20, 2012, 8:02 AM Bayer (BAYZF.PK) decides to avoid getting enmeshed in a bidding war for Schiff Nutrition (SHF -5.3%), saying it won't increase its $1.2B proposal for the U.S. company after Reckitt Benckiser (RBGPF.PK) offered $1.4B. "Entering a competitive bidding process in response to the November 18 Proposal (Reckitt's bid) would result in a price outside Bayer's set financial criteria," the German drug maker says. Comment! [Healthcare, On the Move, M&A]
Friday, November 16, 2012, 5:14 AM Schiff Nutrition (SHF) shares surged 30% to $44.10 in post-market trading after it became the subject of a bidding war. Reckitt Benckiser (RBGPF.PK) has offered $1.4B, or $42/share, to acquire Schiff, topping a $1.2B proposal from Bayer (BAYZF.PK). Buying Schiff would enable Reckitt to enter the $30B market for vitamins and supplements, a temptation that analysts think could prompt J&J (JNJ) into making a bid as well. Comment! [Financials, Consumer]
Tuesday, October 30, 2012, 4:44 AM Bayer (BAYZF.PK) agrees to acquire Schiff Nutrition (SHF) for $1.2B in cash, with the $34-a-share offer representing a 47% premium to the latter's close on Friday. The deal strengthens Bayer's presence in the U.S., the biggest market in the world for over-the-counter and nutritional products. Separately, Bayer's Q3 EBITDA edges up to €1.85B as sales rise 12% to €9.67B. (PR: merger, earnings) Comment! [Healthcare, M&A]
Monday, August 27, 2012, 9:03 AM The FDA sends Genzyme a "refuse to file" letter in which it asks the Sanofi (SNY) unit to change the presentation of the data in a filing for the firm's Lemtrada treatment for multiple sclerosis so that the application is easier to navigate. The FDA has not requested additional data for further studies for Lemtrada, which could be launched in 2013 if the FDA approves it. (PR) Comment! [Healthcare]
Monday, July 23, 2012, 9:07 AM The combination of Tarceva and Nexavar tablets to treat liver cancer didn't improve survival rates compared with Nexavar on its own in a Phase III trial. Nexavar is jointly produced by Bayer and Onyx (ONXX -0.45%), while Tarceva, which is already used in lung cancer, is sold by Astellas Pharma and Roche unit Genentech. Comment! [Healthcare]
Thursday, June 28, 2012, 3:28 AM The FDA grants priority review to a cancer drug from Onyx Pharmaceuticals (ONXX) and Bayer AG (BAYRY.PK), meaning the FDA will review the drug in six months instead of the standard ten. Regorafenib is meant to treat metastatic colorectal cancer for patients in whom the disease has worsened after standard therapy. Comment! [Healthcare]

Country: United States

Currently, there's no company description for BAYZF.PK.

BAYZF.PK Bayer Ag Ord

BAYZF.PK

Bayer Ag Ord